anurajms/meta_analysis huggingface dataset:
outcomes:
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Cystic Fibrosis Pulmonary Exacerbation 4. Quality of Life 5. Antibiotic resistance test 6. Death 7. Duration Of Hospital Stay 8. Lung function test 9. Adverse Event 10. Survival 11. Respiratory Tract Infection
outcomes:
Pharmacological interventions for pain and sedation management in newborn infants undergoing therapeutic hypothermia
1. Analgesia 2. Astrid Lindgren and Lund Children's Hospital's Pain and Stress Assessment Scale for Preterm and Sick Newborn Infants 3. All Cause Mortality 4. Pain 5. Douleur Aigue du Nouveau-ne 6. Sedation 7. Crying, Requires oxygen, Increased vital signs, Expression, Sleepless scale 8. Neonatal Facial Coding System 9. Neonatal, Pain, Agitation and Sedation Scale
outcomes:
Support for healthy breastfeeding mothers with healthy term babies
1. Breastfeeding Stopped
outcomes:
Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care
1. Complete recovery 2. Death 3. Antibiotic Therapy 4. Clinical Improvement
outcomes:
Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis
1. Infection 2. Uveitis 3. Adverse Event
outcomes:
Splinting for the non‐operative management of developmental dysplasia of the hip (DDH) in children under six months of age
1. Skin pressure mark 2. Surgery 3. Nerve Palsy 4. Avascular Necrosis 5. Femoral nerve palsy
outcomes:
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
1. Emergency Care 2. Serious Adverse Event 3. Patient-initiated Visit to General Practitioner 4. Treatment Failure 5. Asthma exacerbation
outcomes:
Laser therapy for treating hypertrophic and keloid scars
1. Keloid Scar 2. Hypertrophic Scar 3. Adverse Event
outcomes:
Appetite stimulants for people with cystic fibrosis
1. Body Composition 2. Increased Appetite 3. Lung function test 4. Body Weight and Growth Problems
outcomes:
Synbiotics, prebiotics and probiotics for solid organ transplant recipients
1. Functional Finding Of Gastrointestinal Tract 2. Serious Adverse Event 3. Transplanted Organ Rejection 4. Quality of Life 5. Death 6. Graft Infection 7. Adverse Event
outcomes:
Fluvoxamine for the treatment of COVID‐19
1. Serious Adverse Event 2. Quality of Life 3. Clinical status 4. Death 5. Adverse Event
outcomes:
Water for wound cleansing
1. Wound Infection
outcomes:
Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients
1. ABC Taxonomy for Medication Adherence
outcomes:
Adding rapid diagnostic tests to community‐based programmes for treating malaria
1. Antimalarial 2. Death 3. Hospitalization
outcomes:
Stiripentol add‐on therapy for drug‐resistant focal epilepsy
1. Seizure
outcomes:
D‐mannose for preventing and treating urinary tract infections
1. Relapse 2. Pain 3. Urinary Tract Infection 4. Clinical Cure
outcomes:
Strategies for enhancing the implementation of school‐based policies or practices targeting diet, physical activity, obesity, tobacco or alcohol use
1. Cost-Benefit Analysis 2. Health-related Behavior Finding 3. Organization and Administration
outcomes:
Memantine for autism spectrum disorder
1. Side effects 2. Autism Spectrum Disorder
outcomes:
Probiotics for preventing acute upper respiratory tract infections
1. Duration of Symptom 2. Adverse Drug Reaction 3. Upper Respiratory Infection 4. Absenteeism 5. Adverse Event 6. Antibiotic Therapy
outcomes:
Psychological therapies for temporomandibular disorders (TMDs)
1. Disability 2. Pain 3. Adverse Event
outcomes:
Physical activity and exercise training in cystic fibrosis
1. Diabetic Monitoring 2. Cystic Fibrosis 3. Forced Expiratory Volume 4. Cystic Fibrosis Pulmonary Exacerbation 5. Perceived Control Of Insulin-dependent Diabetes 6. Death 7. Exercise Capacity 8. Lung function test 9. Adverse Event 10. Health-Related Quality of Life
outcomes:
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Employee absenteeism 4. Cystic Fibrosis Pulmonary Exacerbation 5. Quality of Life 6. Intravenous Therapy 7. Absenteeism 8. Lung function test 9. Adverse Event 10. Time-to-Event 11. Antibiotic Therapy 12. Microbiology test
outcomes:
Anti‐IL‐5 therapies for asthma
1. Quality of Life 2. Hospitalization 3. Lung function test 4. Asthma exacerbation 5. Adverse Event 6. Eosinophils
outcomes:
Child protection training for professionals to improve reporting of child abuse and neglect
1. Victim of child abuse 2. Serious Reportable Event 3. Medical Record
outcomes:
Short‐acting inhaled bronchodilators for cystic fibrosis
1. Forced Expiratory Volume 1 2. Cystic Fibrosis Pulmonary Exacerbation 3. Quality of Life 4. Cystic Fibrosis Quality of Life 5. Cystic Fibrosis Questionnaire-Revised
outcomes:
Exercise versus airway clearance techniques for people with cystic fibrosis
1. Forced Expiratory Volume 2. Quality of Life 3. Respiratory Function 4. Exercise Capacity 5. Cystic Fibrosis Questionnaire-Revised 6. Adverse Event 7. Antibiotic Therapy
outcomes:
Interventions to improve water, sanitation, and hygiene for preventing soil‐transmitted helminth infection
1. Soil-transmitted helminth infection
outcomes:
Non‐pharmacological interventions for sleep promotion in hospitalized children
1. Sleep Finding 2. Polysomnogram
outcomes:
Digital interventions to improve adherence to maintenance medication in asthma
1. Monitoring Adherence To Medication Regime 2. Corticosteroids 3. Asthma exacerbation 4. Asthma
outcomes:
Antibiotics for the induction and maintenance of remission in ulcerative colitis
1. Relapse 2. Inadequate Clinical Response To Medication 3. Serious Adverse Event 4. Quality of Life 5. Remission 6. Withdrawn 7. Adverse Event
outcomes:
Community‐based interventions for improving mental health in refugee children and adolescents in high‐income countries
1. Mental Health Assessment 2. Adverse Event
outcomes:
Music therapy for autistic people
1. Social Interaction 2. Quality of Life 3. Autism Spectrum Disorder 4. Non-verbal Communication 5. Clinical Global Impression 6. Verbal Communication 7. Adverse Event
outcomes:
Care delivery and self‐management strategies for children with epilepsy
1. Healthcare costs 2. Patient knowledge 3. Quality of Life 4. Seizure 5. Social functioning 6. Health Status 7. Drug toxicity
outcomes:
Probiotics for the prevention of Hirschsprung‐associated enterocolitis
1. Serious Adverse Event 2. Recurrent Disease 3. Death 4. Hirschsprung-associated enterocolitis
outcomes:
Negative pressure wound therapy for surgical wounds healing by primary closure
1. Surgical Site Infection 2. All Cause Mortality 3. Costs and Cost Analysis 4. Pain 5. Seroma 6. Repeat surgery 7. Hematoma 8. Quality of Life 9. Blister 10. Readmission 11. Wound Dehiscence
outcomes:
Fortification of salt with iron and iodine versus fortification of salt with iodine alone for improving iron and iodine status
1. Blood Pressure 2. Urinary iodine concentration 3. Hemoglobin concentration
outcomes:
Continuous positive airway pressure (CPAP) for acute bronchiolitis in children
1. Respiratory Rate 2. Clinical Resolution 3. Mechanical ventilation 4. Time-to-Event
outcomes:
Prophylactic cyclo‐oxygenase inhibitor drugs for the prevention of morbidity and mortality in preterm infants: a network meta‐analysis
1. Chronic Lung Disease 2. Neonatal Necrotizing Enterocolitis 3. Intraventricular Hemorrhage 4. Pharmacotherapy 5. Periventricular Leukomalacia 6. Death 7. Cerebral Palsy 8. Neurodevelopmental Disorder 9. Oliguria 10. Gastrointestinal Perforation 11. Ventricular Hemorrhage
outcomes:
Probiotics for treatment of chronic constipation in children
1. Faecal incontinence 2. Serious Adverse Event 3. Treatment Success 4. Fecal Disimpaction 5. Withdrawal Due To Adverse Events 6. Adverse Event 7. Defecation 8. Encopresis
outcomes:
Unconditional cash transfers for reducing poverty and vulnerabilities: effect on use of health services and health outcomes in low‐ and middle‐income countries
1. Child labour 2. Poverty 3. Education 4. Death 5. Depression 6. Nutritional status 7. Nutritional Stunting
outcomes:
Oral dextrose gel for the treatment of hypoglycaemia in newborn infants
1. Sensorineural Hearing Loss 2. Intellect Impaired 3. Blindness 4. Developmental Delay 5. Breast Fed 6. Hypoglycemia 7. Cerebral Palsy 8. Adverse Event 9. Neurodevelopmental Delay
outcomes:
Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age
1. Lower Respiratory Tract Infection 2. All Cause Mortality 3. Bitot's Spots 4. Vomiting 5. Measles 6. Vitamin A Deficiency 7. Diarrhoea 8. Night Blindness
outcomes:
Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1. Adverse Event
outcomes:
Synbiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1. Infection 2. All Cause Mortality 3. Necrotizing Enterocolitis 4. Duration Of Hospital Stay 5. Hospitalization 6. Neurodevelopmental Delay
outcomes:
Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
1. Conners' Adult ADHD Rating Scales 2. Motor Vehicle Traffic Accident 3. Serious Adverse Event 4. Attention Deficit Hyperactivity Disorder 5. Daily living activities 6. Delinquent Behavior 7. Absenteeism Or Truancy 8. Marital Problem
outcomes:
Clonazepam monotherapy for treating people with newly diagnosed epilepsy
1. Seizure 2. Adverse Event
outcomes:
Sealants for preventing dental caries in primary teeth
1. Retention Of Dental Device On Tooth Following Dental Procedure 2. Dental Caries 3. Adverse Event
outcomes:
Binocular versus standard occlusion or blurring treatment for unilateral amblyopia in children aged three to eight years
1. Visual Acuity Testing
outcomes:
Antiepileptic drugs for the primary and secondary prevention of seizures after stroke
1. Seizure
outcomes:
Low‐carbohydrate versus balanced‐carbohydrate diets for reducing weight and cardiovascular risk
1. Weight Loss 2. Diastolic Blood Pressure 3. Body weight 4. Cardiovascular Mortality 5. Low Density Lipoprotein Cholesterol Measurement 6. Constipation
outcomes:
Cuffed versus uncuffed endotracheal tubes for neonates
1. Stridor 2. All Cause Mortality 3. Surgery 4. Post-intubation Subglottic Stenosis 5. Endotracheal Reintubation 6. Extubation
outcomes:
Oral antihistamine‐decongestant‐analgesic combinations for the common cold
1. Side effects 2. Clinical effectiveness 3. Physician's Global Evaluation
outcomes:
Delayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infants
1. Infection 2. Feeding intolerance 3. Necrotizing Enterocolitis 4. Death
outcomes:
Rapid versus slow withdrawal of antiepileptic drugs
1. Quality of Life 2. Death 3. Seizure
outcomes:
Intermittent prophylactic antibiotics for bronchiectasis
1. Acute Exacerbation Of Bronchiectasis 2. Serious Adverse Event 3. St George Hospital Respiratory Questionnaire 4. Quality of Life Questionnaire-Respiratory 5. Hospitalization 6. Antimicrobial resistance 7. Health-Related Quality of Life
outcomes:
Orthodontic treatment for crowded teeth in children
1. Crowding Of Teeth
outcomes:
Orthodontic treatment for posterior crossbites
1. Posture Correction
outcomes:
Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis
1. Perforation Of Intestine 2. Rectal Hemorrhage 3. Distal Intestinal Obstruction Syndrome 4. Anaphylaxis 5. Mucosal erosion 6. Vomiting 7. Treatment Failure 8. Clinical Resolution 9. Abdominal Pain 10. Abdominal Mass 11. Time-to-Event
outcomes:
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis
1. Gastrointestinal Symptom 2. Distal Intestinal Obstruction Syndrome 3. Serious Adverse Event 4. Drug Tolerance 5. Quality of Life 6. Hospitalization 7. Adverse Event 8. Symptom severity
outcomes:
Transfusion thresholds for guiding red blood cell transfusion
1. Infection 2. Myocardial Infarction 3. Stroke 4. Congestive Heart Failure 5. Red Blood Cell Transfusion 6. Death 7. Rebleeding 8. Thromboembolism
outcomes:
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
1. All Cause Mortality 2. Hearing impairment 3. Blindness 4. Developmental Delay 5. Neonatal Seizure 6. Cerebral Palsy 7. Neurodevelopmental Delay
outcomes:
Peer support interventions for parents and carers of children with complex needs
1. Able To Cope 2. Self-confidence Finding 3. Self Efficacy 4. Psychological distress 5. Stigma 6. Social Support 7. Quality of Life 8. Carer Able To Cope 9. Mood Depressions 10. Life satisfaction
outcomes:
Nifedipine for primary dysmenorrhoea
1. Headache 2. Flushing 3. Numerical Rating Scale 4. Binary Individualized Outcome Measure 5. Drug Therapy 6. Feeling Faint 7. Visual Analog Scale 8. Low Blood Pressure 9. Adverse Event 10. Health-Related Quality of Life 11. Dizziness 12. Tachycardia 13. Pain 14. Palpitations
outcomes:
Autogenic drainage for airway clearance in cystic fibrosis
1. Exercise Tolerance Finding 2. Forced Expiratory Volume 3. Quality of Life 4. Hospitalization 5. Adverse Event
outcomes:
Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis
1. Forced Expiratory Volume 1 2. Serious Adverse Event 3. Cystic Fibrosis Pulmonary Exacerbation 4. Death 5. Hospitalization 6. Lung function test 7. Adverse Event 8. Time-to-Event
outcomes:
Chemotherapy for second‐stage human African trypanosomiasis: drugs in use
1. Serious Adverse Event 2. Death 3. African Trypanosomiasis 4. Adverse Event
outcomes:
Antibiotics for treatment of sore throat in children and adults
1. Glomerulonephritis 2. Sore Throat 3. Otitis Media 4. Rheumatic Fever 5. Peritonsillar Abscess
outcomes:
Pharmacological treatment for psychotic depression
1. Withdrawn From Research Study 2. Depression 3. Therapeutic Response
outcomes:
Carisbamate add‐on therapy for drug‐resistant focal epilepsy
1. Seizure
outcomes:
Parenteral versus enteral fluid therapy for children hospitalised with bronchiolitis
1. Likert Scale 2. Length Of Stay 3. Complication 4. Management Of Fluid Therapy 5. Parent satisfaction
outcomes:
Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline
1. Forced Vital Capacity 2. Acute Respiratory Infections 3. Quality of Life 4. Hospitalization 5. Adverse Event
outcomes:
Nasal continuous positive airway pressure levels for the prevention of morbidity and mortality in preterm infants
1. Treatment Failure 2. Bronchopulmonary Dysplasia Of Newborn 3. Death 4. Mechanical ventilation 5. Neurodevelopmental Delay
outcomes:
Topiramate for juvenile myoclonic epilepsy
1. Seizure 2. Seizure Free 3. Adverse Event
outcomes:
Non‐corticosteroid adjuvant therapies for acute bacterial meningitis
1. All Cause Mortality 2. Hearing impairment 3. Sequelae Of Neurological Disorders 4. Death 5. Adverse Event
outcomes:
Vaccines for measles, mumps, rubella, and varicella in children
1. Rubella 2. Measles 3. Varicella 4. Mumps
outcomes:
Macrolides versus placebo for chronic asthma
1. Medication Dose Decreased 2. Quality of Life 3. Death 4. Hospitalization 5. Lung function test 6. Adverse Event 7. Asthma exacerbation 8. Asthma
outcomes:
Vitamin C supplementation for prevention and treatment of pneumonia
1. Pneumonia 2. Urticarias 3. Death 4. Adverse Event
outcomes:
Vaccines for preventing rotavirus diarrhoea: vaccines in use
1. All Cause Mortality 2. Serious Adverse Event 3. Intussusception 4. Diarrhea 5. Diarrhoea Rotavirus
outcomes:
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children
1. Wheezing 2. Death 3. Hospitalization 4. Adverse Event 5. Respiratory Syncytial Virus Infection
outcomes:
Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
1. Disability 2. Bronchopulmonary Dysplasia Of Newborn 3. Hearing impairment 4. Blindness 5. Death 6. Cerebral Palsy 7. Oxygen Supplementation
outcomes:
Decision coaching for people making healthcare decisions
1. Decision making 2. Healthcare Decision Making 3. Adverse Event 4. Patient-Reported Outcome
outcomes:
Antiepileptic drugs for seizure control in people with neurocysticercosis
1. Seizure
outcomes:
Phototherapy for atopic eczema
1. Atopic Dermatitis 2. Visual Analog Scale 3. Withdrawal Due To Adverse Events 4. Severity Scoring of Atopic Dermatitis Index 5. Health-Related Quality of Life 6. Patient-Reported Outcome
outcomes:
Intermittent catheter techniques, strategies and designs for managing long‐term bladder conditions
1. Costs and Cost Analysis 2. Urinary Tract Infection 3. Adverse Event 4. Patient-Reported Outcome
outcomes:
Avoidance of bottles during the establishment of breastfeeds in preterm infants
1. Infection 2. Breast Fed 3. Duration Of Hospital Stay
outcomes:
Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
1. Disability 2. Chronic Lung Disease 3. Hearing impairment 4. Blindness 5. Death 6. Cerebral Palsy
outcomes:
Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma
1. Quality of Life 2. Adverse Event 3. Asthma exacerbation
outcomes:
Prophylactic or very early initiation of continuous positive airway pressure (CPAP) for preterm infants
1. Pneumothorax 2. Intraventricular Hemorrhage 3. Bronchopulmonary Dysplasia Of Newborn 4. Death 5. Recurrent Apnea 6. Mechanical ventilation
outcomes:
Provision of folic acid for reducing arsenic toxicity in arsenic‐exposed children and adults
1. All Cause Mortality 2. Congenital Malformation 3. Cancer 4. Cognitive impairment
outcomes:
Materials for retrograde filling in root canal therapy
1. Pain 2. Arrest Of Bone Development And/or Growth 3. Dental Filling Failure
outcomes:
Pharmacotherapy for trichotillomania
1. Clinical Global Impression 2. Therapeutic Response 3. Clinical Improvement
outcomes:
Sulthiame monotherapy for epilepsy
1. Treatment Failure
outcomes:
Treatments for seizures in catamenial (menstrual‐related) epilepsy
1. Seizure
outcomes:
Non‐pharmacological interventions for stuttering in children six years and younger
1. Frequency of symptom 2. Stuttering 3. Speech efficiency
outcomes:
Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
1. Obsessive-compulsive Disorder 2. Adverse Event
outcomes:
Vitamin D supplementation for chronic liver diseases in adults
1. All Cause Mortality 2. Serious Adverse Event 3. Death
outcomes:
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Cystic Fibrosis Pulmonary Exacerbation 4. Body weight 5. Quality of Life 6. Hospitalization 7. Fasting Blood Glucose 8. Lung function test 9. Height and growth measurements 10. Nutritional Finding 11. Height Increased
outcomes:
Heliox for croup in children
1. Heart Rate 2. Respiratory Rate 3. Duration Of Hospital Stay 4. Hospitalization 5. Intubation 6. Adverse Event 7. Croup 8. Health Care Utilization
outcomes:
Chloral hydrate as a sedating agent for neurodiagnostic procedures in children
1. Sedated 2. Neurologic Diagnostic Procedures
outcomes:
Direct composite resin fillings versus amalgam fillings for permanent posterior teeth
1. Dental Filling Failure 2. Adverse Event
outcomes:
Continuous versus bolus intermittent intragastric tube feeding for preterm and low birth weight infants with gastro‐oesophageal reflux disease
1. Gastroesophageal Reflux Disease
outcomes:
Push versus gravity for intermittent bolus gavage tube feeding of preterm and low birth weight infants
1. Heart Rate 2. Respiratory Rate 3. Tube Feeding Diet 4. Enteral Feeding Intolerance
outcomes:
Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis
1. Intestinal Malabsorption Of Fat 2. Adverse Event 3. Nutritional status
outcomes:
Schedules for home visits in the early postpartum period
1. Neonatal Death 2. Maternal Death
outcomes:
Opioid treatment for opioid withdrawal in newborn infants
1. Treatment Failure 2. Death 3. Seizure 4. Neurodevelopmental Delay
outcomes:
Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates
1. Jaundice 2. Kernicterus Of Newborn 3. Treatment Failure 4. Death 5. Hospitalization 6. Readmission 7. Phototherapy Of Newborn 8. Hypothermia
outcomes:
Bisphosphonate use in children with cerebral palsy
1. Bone Density 2. Fracture
outcomes:
Ivermectin treatment in humans for reducing malaria transmission
1. Malaria 2. Mosquito mortality
outcomes:
Altered dietary salt intake for people with chronic kidney disease
1. All Cause Mortality 2. Cardiovascular Mortality
outcomes:
Continuous nasogastric milk feeding versus intermittent bolus milk feeding for preterm infants less than 1500 grams
1. Enteral nutrition 2. Growth 3. Head Circumference 4. Necrotizing Enterocolitis 5. Total Parenteral Nutrition 6. Hospitalization 7. Enteral Feeding Intolerance 8. Weight Gain 9. Has Grown In Height
outcomes:
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
1. Seizure
outcomes:
Prophylactic drug management for febrile seizures in children
1. Febrile Convulsion
outcomes:
Oral antibiotics for chronic blepharitis
1. Schirmer's Test 2. Bacterial Culture 3. Decreased Tear Film Break-up Time 4. Adverse Event 5. Clinical Improvement
outcomes:
Topical azole treatments for otomycosis
1. Allergic Reaction 2. Mycological Cure 3. Otomycosis 4. Adverse Event
outcomes:
New generation antidepressants for depression in children and adolescents: a network meta‐analysis
1. Depression 2. Suicide
outcomes:
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide‐treated nets to prevent malaria in Africa
1. Malaria 2. Parasitic infection 3. Mosquito mortality 4. Bite Of Mosquito
outcomes:
Internet‐based cognitive and behavioural therapies for post‐traumatic stress disorder (PTSD) in adults
1. Treatment Withdrawal 2. Costs and Cost Analysis 3. Posttraumatic Stress Disorder 4. Depressive symptoms 5. Anxiety Symptoms 6. Adverse Event
outcomes:
Sedatives for opioid withdrawal in newborn infants
1. Treatment Failure 2. Death 3. Seizure 4. Neurodevelopmental Delay
outcomes:
Antibiotic regimens for early‐onset neonatal sepsis
1. All Cause Mortality 2. Serious Adverse Event 3. Neurological Impairment 4. Necrotizing Enterocolitis 5. Nephrotoxicity
outcomes:
Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma
1. Forced Expiratory Volume 1 2. Emergency Care 3. Quality of Life 4. Hospitalization 5. Asthma exacerbation 6. Rescue Medication 7. Mini Asthma Quality Of Life Questionnaire
outcomes:
Rubber dam isolation for restorative treatment in dental patients
1. Tooth Restoration Failure 2. Adverse Event
outcomes:
Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome
1. Disability 2. All Cause Mortality 3. Bronchopulmonary Dysplasia Of Newborn 4. Neonatal Pulmonary Air Leak 5. Neurosensory disability 6. Death 7. Intubation 8. Perinatal Intraventricular Hemorrhage 9. Survival
outcomes:
Topical emollient for preventing infection in preterm infants
1. Infection 2. Coagulase Negative Staphylococcal Infection 3. Bacterial Infection 4. Death 5. Fungal Infection
outcomes:
Paying for performance to improve the delivery of health interventions in low‐ and middle‐income countries
1. Employee absenteeism 2. Fiscal Resource Management 3. Treatment Success 4. Death 5. Quality of care 6. Patient Satisfaction 7. Information System
outcomes:
Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure
1. Epileptic Seizure 2. Seizure
outcomes:
Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection
1. Death 2. Duration Of Hospital Stay
outcomes:
Drug therapies for reducing gastric acidity in people with cystic fibrosis
1. Hyperchlorhydria 2. Complication 3. Nutritional status
outcomes:
Cough augmentation techniques for people with chronic neuromuscular disorders
1. Quality of Life 2. Length Of Stay 3. Peak Flow Rate 4. Adverse Event 5. Emergency Hospital Admission 6. Patient Satisfaction
outcomes:
Antidepressants for people with epilepsy and depression
1. Depression 2. Seizure
outcomes:
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
1. All Cause Mortality 2. Serious Adverse Event 3. Asthma-Related Death 4. Asthma
outcomes:
Anti‐seizure medications for Lennox‐Gastaut syndrome
1. Seizure
outcomes:
Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions
1. Pain 2. Serious Adverse Event 3. Operation time 4. Visual Analog Scale 5. Adverse Event 6. Patient Satisfaction
outcomes:
Lung recruitment manoeuvres for reducing mortality and respiratory morbidity in mechanically ventilated neonates
1. Length of ICU Stay 2. Bronchopulmonary Dysplasia Of Newborn 3. Continuous Positive Airway Pressure Ventilation 4. Death 5. Duration Of Hospital Stay 6. Oxygen Supplementation 7. Respiratory support
outcomes:
Dornase alfa for cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Clearance Of Secretions Of Respiratory Tract 4. Cystic Fibrosis Pulmonary Exacerbation 5. Quality of Life 6. Lung function test
outcomes:
Opioids for newborn infants receiving mechanical ventilation
1. Pain 2. Death 3. Mechanical ventilation 4. Neurodevelopmental Delay
outcomes:
Zinc supplementation for improving pregnancy and infant outcome
1. Small For Gestational Age 2. Birth Weight 3. Stillbirth 4. Premature Labor 5. Premature Birth Of Newborn 6. Neonatal Death 7. Low Birth Weight Infant
outcomes:
Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates
1. Bacterial Sepsis 2. All Cause Mortality 3. Retinopathy Of Prematurity 4. Zinc Deficiency 5. Bronchopulmonary Dysplasia Of Newborn 6. Blood copper level 7. Necrotizing Enterocolitis 8. Blood Iron Status 9. Neurodevelopmental Disorder
outcomes:
High versus standard volume enteral feeds to promote growth in preterm or low birth weight infants
1. Growth 2. Feeding intolerance 3. Head Circumference 4. Necrotizing Enterocolitis 5. Height and growth measurements 6. Weight Gain
outcomes:
Timing of dornase alfa inhalation for cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Forced Expiratory Volume 4. Quality of Life 5. Clinical Finding 6. Lung function test 7. Adverse Event
outcomes:
Interventions for self‐harm in children and adolescents
1. Self-harm
outcomes:
High‐flow nasal cannulae for respiratory support in adult intensive care patients
1. All Cause Mortality 2. Treatment Failure 3. Adverse Event
outcomes:
(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus
1. All Cause Mortality 2. Stroke 3. HbA1c level 4. Serious Adverse Event 5. Hypoglycemia 6. Health-Related Quality of Life 7. Non-fatal Myocardial Infarction
outcomes:
Interventions for bacterial folliculitis and boils (furuncles and carbuncles)
1. Clinical Cure
outcomes:
Antibiotics to prevent complications following tooth extractions
1. Dry socket 2. Trismus 3. Pain 4. Swelling 5. Postoperative Wound Infection 6. Adverse Event 7. Fever
outcomes:
Patient and lay carer education for preventing pressure ulceration in at‐risk populations
1. Pressure ulcer
outcomes:
Fluid restriction in the management of transient tachypnea of the newborn
1. Hypernatremia 2. Weight Loss 3. Duration Of Hospital Stay 4. Hypoglycemia 5. Non-invasive mechanical ventilation 6. Endotracheal Tube 7. Mechanical ventilation 8. Time-to-Event 9. Oxygen Supplementation 10. Respiratory support
outcomes:
The effectiveness and adverse effects of D‐cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder
1. Social Interaction 2. Adverse Drug Reaction 3. Communication skills 4. Stereotypies And Automatisms 5. Suicidal Ideation
outcomes:
Topical versus systemic antibiotics for chronic suppurative otitis media
1. Hearing 2. Serious Reportable Event 3. Otalgia 4. Quality of Life 5. Death 6. Earache 7. Chronic Suppurative Otitis Media 8. Otorrhea 9. Ototoxicity
outcomes:
Salbutamol for transient tachypnea of the newborn
1. Continuous Positive Airway Pressure Ventilation 2. Hospitalization 3. Mechanical ventilation 4. Oxygen Supplementation
outcomes:
Systemic antibiotics for chronic suppurative otitis media
1. Hearing 2. Otalgia 3. Serious Reportable Event 4. Quality of Life 5. Death 6. Earache 7. Chronic Otitis Media 8. Otorrhea 9. Ototoxicity
outcomes:
Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease
1. Dialysis Care 2. Infection Of Tunnel Site Of Tunneled Central Venous Catheter 3. Bacteraemia 4. Malfunction Of Peritoneal Dialysis Catheter 5. Peritonitis
outcomes:
Beta‐blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. All Cause Mortality 2. Serious Adverse Event 3. Health-Related Quality of Life
outcomes:
Surgical interventions for the early management of Bell's palsy
1. Complete recovery 2. Muscle Contracture 3. Synkinesis Of Face 4. Clinical Resolution 5. Adverse Event 6. Facial Nerve Function Study 7. Time-to-Event
outcomes:
Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis
1. All Cause Mortality 2. Serious Adverse Event 3. Health-Related Quality of Life
outcomes:
Effect of atorvastatin on testosterone levels
1. Male Sex Hormones - Serum Measurement 2. Withdrawn From Research Study 3. Testosterone level 4. Adverse Event
outcomes:
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents
1. Electroencephalogram 2. Seizure 3. Adverse Event 4. Hyperventilation
outcomes:
Antibiotic therapy versus no antibiotic therapy for children aged 2 to 59 months with WHO‐defined non‐severe pneumonia and wheeze
1. Relapse 2. Treatment Failure 3. Clinical Cure
outcomes:
Interventions for treating iron deficiency anaemia in inflammatory bowel disease
1. Serious Adverse Event 2. Therapeutic Response
outcomes:
Indomethacin for symptomatic patent ductus arteriosus in preterm infants
1. Mucocutaneous Ulcer 2. All Cause Mortality 3. Patent Ductus Arteriosus Ligation 4. Bronchopulmonary Dysplasia Of Newborn 5. Treatment Failure 6. Necrotizing Enterocolitis 7. Gastrointestinal Bleeding
outcomes:
Early full enteral feeding for preterm or low birth weight infants
1. Growth 2. Necrotizing Enterocolitis 3. Head Circumference 4. Weight Gain
outcomes:
Oral hygiene care for critically ill patients to prevent ventilator‐associated pneumonia
1. Ventilator Associated Pneumonia 2. Death
outcomes:
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
1. Symptomatic Recurrent Venous Thrombosis 2. Death 3. Pulmonary Embolism 4. Haemorrhage 5. Major Bleed
outcomes:
Respiratory muscle training for cystic fibrosis
1. Forced Vital Capacity 2. Forced Expiratory Volume 3. Quality of Life 4. Respiratory Function 5. Lung function test 6. Exercise Capacity Decreased
outcomes:
Magnesium sulphate for treating acute bronchiolitis in children up to two years of age
1. Outcome Of Delivery 2. Death 3. Hospitalization 4. Lung function test 5. Intensive Care 6. Mechanical ventilation
outcomes:
Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age
1. Hypercalcemia 2. Hypercalciuria 3. Hyperphosphatemia 4. Body Height 5. Kidney Stone 6. Childhood growth and development 7. Nutritional Stunting
outcomes:
Vitamin D supplementation for term breastfed infants to prevent vitamin D deficiency and improve bone health
1. Bone Density 2. Rickets 3. Vitamin Toxicity 4. Vitamin D Deficiency 5. Adverse Event
outcomes:
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants
1. Chronic Lung Disease 2. All Cause Mortality 3. Intraventricular Hemorrhage 4. Pharmacotherapy 5. Necrotizing Enterocolitis 6. Ligation Of Patent Ductus Arteriosus 7. Duration Of Hospital Stay 8. Neurodevelopmental Delay 9. Transcatheter Device Closure
outcomes:
N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure
1. All Cause Mortality 2. Serious Adverse Event 3. Liver transplant
outcomes:
Interventions to increase patient and family involvement in escalation of care for acute life‐threatening illness in community health and hospital settings
1. Self Efficacy 2. Competence 3. Clinical effectiveness 4. Patient knowledge 5. Client Participation 6. Health-related Behavior Finding 7. Adverse Event 8. Time-to-Event 9. Morbidity 10. Patient Satisfaction 11. Patient-Reported Outcome 12. Carer-Reported Outcome 13. Attitude 14. Death 15. Health Care Utilization
outcomes:
Probiotics for treating acute infectious diarrhoea
1. Diarrhoea
outcomes:
Pneumococcal conjugate vaccines for preventing acute otitis media in children
1. Serious Adverse Event 2. Adverse Event 3. Acute Otitis Media
outcomes:
Individualized versus standard diet fortification for growth and development in preterm infants receiving human milk
1. Retinopathy Of Prematurity 2. Growth 3. Body weight 4. Bronchopulmonary Dysplasia Of Newborn 5. Late Onset Neonatal Sepsis 6. Necrotizing Enterocolitis 7. Head Circumference 8. Death 9. Duration Of Hospital Stay 10. Height and growth measurements 11. Osteopenia
outcomes:
Comparison of different protein concentrations of human milk fortifier for promoting growth and neurological development in preterm infants
1. Body Composition 2. Small For Gestational Age 3. Growth 4. Hearing impairment 5. Blindness 6. Developmental Delay 7. Head Circumference 8. Death 9. Weight Gain 10. Cerebral Palsy 11. Height and growth measurements 12. Neurodevelopmental Delay
outcomes:
Mechanically assisted walking training for walking, participation, and quality of life in children with cerebral palsy
1. Pain 2. Paediatric Quality of Life Inventory 3. Injury 4. Mobility function 5. Quality of Life 6. Gross Motor Function Measure 7. Motor function 8. Participation In Leisure Activity 9. Walk Test
outcomes:
Cognitive behavioural therapy for anxiety disorders in children and adolescents
1. Diagnostic Interview For Children And Adolescents 2. Remission
outcomes:
Band ligation versus sclerotherapy for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. All Cause Mortality 2. Serious Adverse Event 3. Quality of Life
outcomes:
Rufinamide add‐on therapy for drug‐resistant epilepsy
1. Dizziness 2. Treatment Withdrawal 3. Headache 4. Vomiting 5. Diplopia 6. Fatigue 7. Seizure 8. Nausea 9. Adverse Event 10. Sleepiness
outcomes:
Pharmacological treatment for continuous spike‐wave during slow wave sleep syndrome and Landau‐Kleffner Syndrome
1. Memory Function Normal 2. Able To Use Language 3. Neuropsychological Testing 4. Intelligence Test/s-b
outcomes:
Pit and fissure sealants versus fluoride varnishes for preventing dental decay in the permanent teeth of children and adolescents
1. Dental Caries
outcomes:
Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea
1. Psqi - Pittsburgh Sleep Quality Index 2. Accident 3. Quality Of Sleep 4. Cardiovascular disease 5. Death 6. Ess - Epworth Sleepiness Scale 7. Daytime Sleepiness 8. Snoring 9. Apnoea Hypopnoea Index
outcomes:
Specialised early intervention teams for recent‐onset psychosis
1. Global Assessment Of Functioning 2. All Cause Mortality 3. Non-urgent Psychiatric Admission 4. Clinical recovery 5. Mental state 6. Mental health services utilization 7. Social functioning 8. Clinical Global Impression
outcomes:
Specialised early intervention teams (extended time) for recent‐onset psychosis
1. All Cause Mortality 2. Non-urgent Psychiatric Admission 3. Clinical recovery 4. Mental state 5. Mental health services utilization 6. Social functioning 7. Clinical Global Impression
outcomes:
Physical activity interventions for people with congenital heart disease
1. Muscular Strength Development Exercise 2. Physical Activity Level 3. Adverse Event 4. Maximal cardiorespiratory fitness 5. Health-Related Quality of Life
outcomes:
Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy
1. Self Efficacy 2. Quality of Life Inventory 3. Quality of Life 4. Medication adherence 5. Epilepsy Self-Efficacy Scale 6. Health-Related Quality of Life
outcomes:
Virtual reality distraction for acute pain in children
1. Acute Pain 2. Adverse Event 3. Pain Intensity
outcomes:
Drug treatments for managing cystic fibrosis‐related diabetes
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Lung function test 4. Nutritional status 5. Poor Glycemic Control 6. Hemoglobin Finding
outcomes:
Early versus delayed continuous positive airway pressure (CPAP) for respiratory distress in preterm infants
1. Treatment Failure 2. Intermittent Positive Pressure Breathing 3. Death
outcomes:
Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants
1. Blood Gases 2. Treatment Failure 3. Death 4. Respiratory Failure 5. Intensive Care 6. Mechanical ventilation
outcomes:
Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases
1. Infection 2. Aerosol reduction
outcomes:
Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass
1. All Cause Mortality 2. Cardiopulmonary Bypass Finding 3. Cardiovascular Mortality 4. Duration Of Hospital Stay 5. Postoperative State 6. Mechanical ventilation 7. Died In Hospital
outcomes:
Household interventions for secondary prevention of domestic lead exposure in children
1. Behavior 2. Neurological Finding 3. Child Development 4. Adverse Event 5. Blood Lead
outcomes:
Branched‐chain amino acid supplementation for improving growth and development in term and preterm neonates
1. Sensorineural Hearing Loss 2. Blindness 3. Developmental Delay 4. Head Circumference 5. Height and growth measurements 6. Weight Gain 7. Cerebral Palsy 8. Neurodevelopmental Delay
outcomes:
Pine bark (Pinus spp.) extract for treating chronic disorders
1. Systolic Blood Pressure 2. Diastolic Blood Pressure 3. Hyperactivity 4. Child Attention Deficit Disorder 5. Diabetic Peripheral Neuropathy 6. Adverse Event 7. All Cause Mortality 8. High Density Lipoprotein Cholesterol Measurement 9. Wechsler Adult Intelligence Scale 10. Salbutamol 11. California Verbal Learning Test 12. Female Sexual Function Index 13. Erectile Dysfunction 14. Bone Alkaline Phosphatase 15. Visual motor coordination 16. Joint Pain 17. International Index Of Erectile Function 18. Clinical Outcome 19. Diabetic ulcer 20. Cognitive Failures Questionnaire 21. Low Density Lipoprotein Cholesterol Measurement 22. Asthma 23. Patient-Reported Outcome 24. Forced Expiratory Volume 1 25. Serious Adverse Event 26. HbA1c level 27. Plasma Testosterone 28. Attentional Capacity Test
outcomes:
Protein supplementation of human milk for promoting growth in preterm infants
1. Growth 2. Head Circumference 3. Duration Of Hospital Stay 4. Height and growth measurements 5. Weight Gain 6. Neurodevelopmental Delay
outcomes:
Interventions for preventing ophthalmia neonatorum
1. Blindness 2. Bacterial Conjunctivitis 3. Chlamydial Conjunctivitis 4. Conjunctivitis 5. Adverse Event 6. Gonococcal Conjunctivitis Neonatorum
outcomes:
Aural toilet (ear cleaning) for chronic suppurative otitis media
1. Serious Reportable Event 2. Otalgia 3. Vertigo 4. Otorrhea 5. Dizziness 6. Hearing 7. Balance Difficulty 8. Quality of Life 9. Meningitis 10. Bleeding From Ear 11. Mastoiditis 12. Earache 13. Chronic Suppurative Otitis Media
outcomes:
Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review
1. Costs and Cost Analysis 2. Infectious Transmissions 3. Death 4. SARS-CoV-2 Virus 5. Incidence
outcomes:
Systemic treatments for eczema: a network meta‐analysis
1. Eczema Area and Severity Index 2. Patient-Reported Outcome 3. Investigator Global Assessment
outcomes:
Carbohydrate supplementation of human milk to promote growth in preterm infants
1. Growth 2. Body weight 3. Feeding intolerance 4. Head Circumference 5. Necrotizing Enterocolitis 6. Duration Of Hospital Stay 7. Height and growth measurements 8. Neurodevelopmental Delay
outcomes:
Psychological and social interventions for the prevention of mental disorders in people living in low‐ and middle‐income countries affected by humanitarian crises
1. Withdrawn From Research Study 2. Posttraumatic Stress Disorder 3. Mental disorder 4. Depression 5. Anxiety 6. Adverse Event
outcomes:
Psychological treatments for people with epilepsy
1. Seizure
outcomes:
Vitamin E supplementation in people with cystic fibrosis
1. Forced Expiratory Volume 1 2. Vitamin E Analysis 3. Retinopathy 4. Peripheral Nerve Disease 5. Hemolytic Anemia 6. Disorder Of Muscle 7. Assessment Using Bmi (body Mass Index) 8. Ataxia 9. Height 10. Cognitive impairment
outcomes:
Hydrosurgical debridement versus conventional surgical debridement for acute partial‐thickness burns
1. Postoperative Infection 2. Wound Healing
outcomes:
Pharmacotherapy for hyperuricaemia in hypertensive patients
1. Withdrawn From Research Study 2. All Cause Mortality 3. Stroke 4. Myocardial Infarction 5. Serious Adverse Event 6. Blood Pressure Alteration 7. Heart Failure 8. Adverse Event
outcomes:
Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis
1. Relapse 2. Treatment Failure 3. Withdrawal Due To Adverse Events 4. Adverse Event 5. Patient compliance
outcomes:
Surgical interventions for primary congenital glaucoma
1. Intraocular Pressure Test
outcomes:
Interventions for American cutaneous and mucocutaneous leishmaniasis
1. Disease Recurrence 2. Clinical Cure 3. Adverse Event
outcomes:
Fat supplementation of human milk for promoting growth in preterm infants
1. Growth 2. Necrotizing Enterocolitis 3. Head Circumference 4. Duration Of Hospital Stay 5. Hospitalization 6. Enteral Feeding Intolerance 7. Weight Gain 8. Height and growth measurements 9. Neurodevelopmental Delay
outcomes:
Antibiotic therapy for pelvic inflammatory disease
1. Fertility 2. Clinical Resolution 3. Length Of Stay 4. Microbiologic Culture Finding Negative 5. Clinical Cure 6. Withdrawal Due To Adverse Events
outcomes:
Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants
1. Sensorineural Hearing Loss 2. Intellect Impaired 3. Blindness 4. Developmental Delay 5. Neonatal Death 6. Cerebral Palsy 7. Neurodevelopmental Delay
outcomes:
Intravenous immunoglobulin for presumed viral myocarditis in children and adults
1. Overall Survival 2. Event-Free Survival 3. Transplantation Of Heart 4. Death 5. Left Ventricular Assist Device
outcomes:
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax
1. Serious Adverse Event 2. Anemia 3. Parasitemia
outcomes:
Digital contact tracing technologies in epidemics: a rapid review
1. Safety Finding
outcomes:
Mobility management to prevent, reduce, or delay driving a car in teenagers
1. Driving frequency 2. Driving distance 3. Predictable Behavior 4. Holds a driving licence 5. Car Crash 6. Driving a car
outcomes:
Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome
1. Finding Of Regularity Of Menstrual Cycle 2. Acne 3. Hirsutism 4. Assessment Using Bmi (body Mass Index)
outcomes:
Oral non‐steroidal anti‐inflammatory drugs versus other oral analgesic agents for acute soft tissue injury
1. Traumatic Injury 2. Pain 3. Swelling 4. Gastrointestinal findings 5. Neurological examination finding 6. Functional ability
outcomes:
Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis
1. Ulcerative Colitis In Remission 2. Treatment Failure 3. Medication adherence 4. Withdrawal Due To Adverse Events 5. Adverse Event 6. Failure 7. Clinical Improvement
outcomes:
Pancreatic enzyme replacement therapy for people with cystic fibrosis
1. Body Mass Index 2. General Finding Of Height 3. Cystic Fibrosis Pulmonary Exacerbation 4. Body weight 5. Frequency Of Defecation 6. Fat Absorption Test 7. Abdominal Pain 8. Adverse Event 9. Nutritional status
outcomes:
Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients
1. Surgical Site Infection 2. Pneumonia 3. Graft loss 4. Septicemia 5. Urinary Tract Infection 6. Death 7. Adverse Event
outcomes:
Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients
1. Renal Function Monitoring 2. Albuminuria 3. Fasting Blood Glucose 4. Hypoglycemia 5. Estimated glomerular filtration rate 6. Survival 7. Delayed Renal Graft Function 8. All Cause Mortality 9. HbA1c level 10. Serious Adverse Event 11. Kidney transplant 12. Withdrawal Due To Adverse Events 13. Creatinine level 14. Renal Dialysis
outcomes:
Early fortification of human milk versus late fortification to promote growth in preterm infants
1. Enteral nutrition 2. Extrauterine growth restriction 3. Infant Feeding Problem 4. Head Circumference 5. Necrotizing Enterocolitis 6. Height and growth measurements 7. Weight Gain
outcomes:
Topical treatment for facial burns
1. Time to clinical recovery 2. Wound Healing 3. Wound Infection
outcomes:
Education of family members to support weaning to solids and nutrition in later infancy in term‐born infants
1. Infant Death 2. Growth 3. Anemia 4. Head Circumference 5. Height and growth measurements 6. Weight Gain 7. Neurodevelopmental Delay
outcomes:
Beta‐blockers for congestive heart failure in children
1. Congestive Heart Failure 2. Echocardiography 3. Heart Transplant 4. Cardiovascular measurement finding 5. Death 6. Adverse Event 7. Investigations
outcomes:
Workplace pedometer interventions for increasing physical activity
1. Body Mass Index 2. Systolic Blood Pressure 3. Workplace injury 4. Physical Activity Level 5. Quality of Life 6. Not reported 7. Sedentary 8. Low Density Lipoprotein Cholesterol Measurement 9. Patient-Reported Outcome
outcomes:
Interventions for the management of obesity in people with bipolar disorder
1. Body Mass Index 2. Quality of Life 3. Adverse Event 4. Patient-Reported Outcome
outcomes:
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Serious Adverse Event 4. Sputum Microbiology Test 5. Cystic Fibrosis Pulmonary Exacerbation 6. Specimen Collection For Microbiology 7. Quality of Life 8. Inflammatory biomarkers 9. Respiratory Function 10. Sputum Finding 11. Adverse Event 12. Antibiotic Therapy
outcomes:
Statins for asthma
1. Forced Expiratory Volume 1 2. Serious Adverse Event 3. Hospitalization 4. Asthma Control 5. Peak Expiratory Flow Rate 6. Asthma exacerbation 7. Health-Related Quality of Life 8. Asthma Control Questionnaire
outcomes:
Head midline position for preventing the occurrence or extension of germinal matrix‐intraventricular haemorrhage in preterm infants
1. Intraventricular Hemorrhage 2. Germinal Matrix Hemorrhage 3. Death
outcomes:
Psychological interventions for psychosis in adolescents
1. Withdrawn From Research Study 2. Cognitive function 3. Hospital admission 4. Mental State Finding 5. Global Assessment 6. Adverse Event 7. Functional ability
outcomes:
Lamotrigine add‐on therapy for drug‐resistant generalised tonic‐clonic seizures
1. Seizure
outcomes:
Use of reflective materials during phototherapy for newborn infants with unconjugated hyperbilirubinaemia
1. Serum Bilirubin level 2. Exchange Transfusion 3. Apparent Life-threatening Event In Infant 4. Phototherapy Of Newborn 5. Breastfeeding At Discharge From Hospital 6. Patient Satisfaction
outcomes:
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
1. Gastrointestinal Symptom 2. All Cause Mortality 3. Cardiac Arrhythmia 4. Cardiovascular Mortality 5. Serum Potassium 6. Constipation 7. Health-Related Quality of Life